sglt2 inhibitor vs glp 1 SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease SGLT2 inhibitors or GLP-1 receptor

10.1016/j.neuron.2007.01.033 Neuron 335 WileyR

Scientists have been working for years to understand the appetite center in the hypothalamus, because they knew that if they could unlock the secrets of this appetite center, they could also discover a key to naturally reducing the appetite, radically changing our approach to weight loss

Inositol-Requiring Kinase 1 regulates apoptosis via inducing endoplasmic reticulum stress in colitis epithelial cells

At least four hypothesizes have been proposed

Big Pharma business-development teams are looking for deals

Side effects from each dose escalation typically begin within 24 to 72 hours of the new dose being administered